Modulation of blood cell gene expression by DHA supplementation in hypertriglyceridemic men
Abstract
Our previous study with docosahexaenoic acid (DHA) supplementation to hypertriglyceridemic men showed that DHA reduced several risk factors for cardiovascular disease, including the plasma concentration of inflammatory markers. To determine the effect of DHA supplementation on the global gene expression pattern, we performed Affymetrix GeneChip microarray analysis of blood cells [treated with lipopolysaccharide (LPS) or vehicle] drawn before and after the supplementation of DHA from the hypertriglyceridemic men who participated in that study. Genes that were significantly differentially regulated by the LPS treatment and DHA supplementation were identified. Differential regulation of 18 genes was then verified by quantitative real-time polymerase chain reaction (qRT-PCR). Both microarray and qRT-PCR data showed that DHA supplementation significantly suppressed the expression of low-density lipoprotein (LDL) receptor and cathepsin L1, both of which were also up-regulated by LPS. DHA supplementation also suppressed oxidized LDL (lectin-like) receptor 1 (OLR1). However, LPS did not induce OLR1 mRNA expression. Enrichment with Gene Ontology categories demonstrated that the genes related to transcription factor activity, immunity, host defense and inflammatory responses were inversely regulated by LPS and DHA. These results provide supporting evidence for the anti-inflammatory effects of DHA supplementation, and reveal previously unrecognized genes that are regulated by DHA and are associated with risk factors of cardiovascular diseases.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment with a DHA-enriched oil or an OM3FA formulation containing both DHA and EPA reduced plasma levels of PCSK9, but not LDL-C.
“Treatment with a DHA-enriched oil [64] or an OM3FA formulation containing both DHA and EPA [65] reduced plasma levels of PCSK9, but not LDL-C.”
Treatment with OM3FAs reduces plasma levels of PCSK9, but does not reduce LDL-C levels.
“Treatment with OM3FAs reduces plasma levels of PCSK9, but does not reduce LDL-C levels.”
The citation lists haven’t been fetched yet
References 42 · Cited by 24
- Authors
- Dawson, K., Zhao, L., Adkins, Y., Vemuri, M., Rodriguez, R. L., Gregg, J. P., Kelley, D. S., & Hwang, D. H.
- Affiliations
- University of California, Davis (US)
- Western Human Nutrition Research Center (US)
- UC Davis Comprehensive Cancer Center (US)
- Corresponding author
- Hwang, Daniel H.
- Venue
- The Journal of Nutritional Biochemistry
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 23
- Issue
- 6
- Pages
- 616-621
- ISSN
- 0955-2863 (ISSN-L)
- OpenAlex
- W2037855075
- Cited by
- 24
- References
- 42
- Citations by year
- 2025: 1 · 2022: 2 · 2019: 1 · 2018: 2 · 2017: 3 · 2016: 7 · 2015: 3 · 2014: 2 · 2012: 3
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Nutritional Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-064007, DK064007-05S1, R01DK064007)
- National Institute on Minority Health and Health Disparities (P60/MD00222, P60MD000222)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
- Physical Sciences › Chemistry › Organic Chemistry › Edible Oils Quality and Analysis
- Keywords
- docosahexaenoic acid, omega-3 supplementation, hypertriglyceridemia, lipopolysaccharide, LDL receptor, cathepsin L, oxidized LDL receptor-1, anti-inflammatory activity, cardiovascular risk factors, inflammation, transcription factor activity
- MeSH terms
- Anti-Inflammatory Agents, Docosahexaenoic Acids, Humans, Inflammation, Lipopolysaccharides, Male, Receptors, LDL, Hypertriglyceridemia, Up-Regulation, Randomized Controlled Trials as Topic, Dietary Supplements, Oligonucleotide Array Sequence Analysis, Scavenger Receptors, Class E, Cathepsin L, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
